Oncology and Hematology - Global Oncology Academy

289-304 of 743

Relapsed or Refractory DLBCL: Reviewing the Expanding Treatment Landscape
Relapsed or Refractory DLBCL: Reviewing the Expanding Treatment Landscape
Project Oncology®
Relapsed or Refractory DLBCL: Reviewing the Expanding Treatment Landscape
MinuteCE®
CDH6 in Focus: Advancing Biomarker-Driven Strategies for Platinum-Resistant Ovarian Cancer
Kathleen N. Moore, MD; Joyce F. Liu, MD, MPH
0.50 credits 5 episodes
- Kathleen N. Moore, MD
- Joyce F. Liu, MD, MPH
0.50 credits 5 episodes
Safety and Tolerability of CDH6-Directed Antibody-Drug Conjugates
Safety and Tolerability of CDH6-Directed Antibody-Drug Conjugates
MinuteCE®
Safety and Tolerability of CDH6-Directed Antibody-Drug Conjugates
Kathleen N. Moore, MD
0.50 program credits
- Kathleen N. Moore, MD
0.50 program credits
Clinical Evidence: Insights From Early Trials of CDH6-Targeted Therapies
Clinical Evidence: Insights From Early Trials of CDH6-Targeted Therapies
MinuteCE®
Clinical Evidence: Insights From Early Trials of CDH6-Targeted Therapies
Joyce F. Liu, MD, MPH
0.50 program credits
- Joyce F. Liu, MD, MPH
0.50 program credits
Navigating the Therapeutic Landscape of Platinum-Resistant Ovarian Cancer
Navigating the Therapeutic Landscape of Platinum-Resistant Ovarian Cancer
MinuteCE®
Navigating the Therapeutic Landscape of Platinum-Resistant Ovarian Cancer
Joyce F. Liu, MD, MPH
0.50 program credits
- Joyce F. Liu, MD, MPH
0.50 program credits
Looking Ahead: Integrating CDH6-Targeted Therapies Into Ovarian Cancer Treatment Paradigms
Looking Ahead: Integrating CDH6-Targeted Therapies Into Ovarian Cancer Treatment Paradigms
MinuteCE®
Looking Ahead: Integrating CDH6-Targeted Therapies Into Ovarian Cancer Treatment Paradigms
Joyce F. Liu, MD, MPH; Kathleen N. Moore, MD
0.50 program credits
- Joyce F. Liu, MD, MPH
- Kathleen N. Moore, MD
0.50 program credits
MOA: CDH6-Targeted Antibody-Drug Conjugates
MOA: CDH6-Targeted Antibody-Drug Conjugates
MinuteCE®
MOA: CDH6-Targeted Antibody-Drug Conjugates
Kathleen N. Moore, MD
0.50 program credits
- Kathleen N. Moore, MD
0.50 program credits
Selecting First-Line Therapy in Gastric Cancers: A Biomarker-Driven Approach
Selecting First-Line Therapy in Gastric Cancers: A Biomarker-Driven Approach
Project Oncology®
Selecting First-Line Therapy in Gastric Cancers: A Biomarker-Driven Approach
Jennifer Caudle, DO, FACOFP; Samuel Klempner, MD
- Jennifer Caudle, DO, FACOFP
- Samuel Klempner, MD
- Nataliya Uboha, MD, PhD
Obesity and Cancer Screening: National Trends and Disparities Revealed
Obesity and Cancer Screening: National Trends and Disparities Revealed
Clinician's Roundtable
Obesity and Cancer Screening: National Trends and Disparities Revealed
Vance Albaugh, MD, PhD
- Vance Albaugh, MD, PhD
Managing MCL After BTKi Failure: The Expanding Role of CAR T-Cell Therapy
Managing MCL After BTKi Failure: The Expanding Role of CAR T-Cell Therapy
Project Oncology®
Managing MCL After BTKi Failure: The Expanding Role of CAR T-Cell Therapy
Charles Turck, PharmD, BCPS, BCCCP; Luhua (Michael) Wang, MD
- Charles Turck, PharmD, BCPS, BCCCP
- Luhua (Michael) Wang, MD
Advancing MPE Diagnosis and Prognosis: Clinical Value of Biomarker Integration
Advancing MPE Diagnosis and Prognosis: Clinical Value of Biomarker Integration
Clinician's Roundtable
Advancing MPE Diagnosis and Prognosis: Clinical Value of Biomarker Integration
David Feller-Kopman, MD
- David Feller-Kopman, MD
Reevaluating Race in Spirometry: Advancing Equity in Pulmonary Risk Assessment
Reevaluating Race in Spirometry: Advancing Equity in Pulmonary Risk Assessment
Project Oncology®
Reevaluating Race in Spirometry: Advancing Equity in Pulmonary Risk Assessment
Modernizing Pulmonary Assessment: Reassessing Race-Neutral Interpretation in Practice
Modernizing Pulmonary Assessment: Reassessing Race-Neutral Interpretation in Practice
Project Oncology®
Modernizing Pulmonary Assessment: Reassessing Race-Neutral Interpretation in Practice
Patient-Reported Outcomes From the Phase 3 KEYNOTE-689 Trial of Adding Perioperative Pembrolizumab to Standard of Care in Resectable Locally Advanced HNSCC
Patient-Reported Outcomes From the Phase 3 KEYNOTE-689 Trial of Adding Perioperative Pembrolizumab to Standard of Care in Resectable Locally Advanced HNSCC
Oncology and Hematology
Patient-Reported Outcomes From the Phase 3 KEYNOTE-689 Trial of Adding Perioperative Pembrolizumab to Standard of Care in Resectable Locally Advanced HNSCC
Yungan Tao
- Yungan Tao
Cohort 9 of the Phase 2 EV-202 Trial: First-Line Enfortumab Vedotin Plus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Cohort 9 of the Phase 2 EV-202 Trial: First-Line Enfortumab Vedotin Plus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Oncology and Hematology
Cohort 9 of the Phase 2 EV-202 Trial: First-Line Enfortumab Vedotin Plus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Paul L Swiecicki, MD
- Paul L Swiecicki, MD
Adjuvant Pembrolizumab Plus Cisplatin-Based Chemoradiation in Locally Advanced HNSCC: First Results From the Randomized Phase 2b ADRISK Trial
Adjuvant Pembrolizumab Plus Cisplatin-Based Chemoradiation in Locally Advanced HNSCC: First Results From the Randomized Phase 2b ADRISK Trial
Oncology and Hematology
Adjuvant Pembrolizumab Plus Cisplatin-Based Chemoradiation in Locally Advanced HNSCC: First Results From the Randomized Phase 2b ADRISK Trial
Yungan Tao
- Yungan Tao

19/11